LOCATION AND LODGING

LOCATION: GILLETTE STADIUM
One Patriot Place | Foxborough, MA 02035
Conference entrance:
West Club (WI Putnam Club)
Visit alumni.mcphs.edu/reed2015 for driving directions and a detailed map of the appropriate stadium entrance.

LODGING:
RENAISSANCE HOTEL & SPA AT PATRIOT PLACE
(Adjacent to Gillette Stadium)
28 Patriot Place, Foxborough, MA 02035
508.543.5500 / 866.580.6236
www.renaissancepatriotplace.com
Special Room Rate: $179 single/double plus applicable tax
Booking Deadline: February 11, 2015
Booking Method: Visit alumni.mcphs.edu/reed2015 for a special booking link or call the phone number above and mention the MCPHS Reed Conference.
Other lodging options are listed at alumni.mcphs.edu/reed2015.

ACCREDITATION
MCPHS University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants will receive 6.0 contact hours (0.6 CEUs), including two hours of pharmacy law, for the live activity and are eligible to complete a complimentary 2.0 hour home study (0.2 CEUs), for a total of 8.0 contact hours (0.8 CEUs).

REQUIREMENTS FOR CREDIT:
Partial credit will not be awarded. All participants must return a signature sheet at the conclusion of the activity to claim credit, as well as log into the MCPHS website, insert the specific activity code for each session, and complete the evaluation. CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours.
Attendance will be verified. Credit will not be issued to participants who arrive more than 15 minutes after the start of that particular session or to those who depart early. Credit cannot be awarded to individuals who complete the activity evaluation(s) more than 60 days post activity.

EVALUATION:
All participants will have the opportunity to review the educational sessions and speakers and to identify future educational needs.

SUPPORT:
A complete list of grant support will be available on the day of the activity.
AGENDA

8:30 AM – 10:00 AM Break / Exhibits
10:00 AM – 10:15 AM Type 2 Diabetes Management: Update on Newer Therapies (Jennifer Goldman-Levine, PharmD, CDE, BC-ADM, FCCP) – 1.0 credits
10:15 AM – 11:45 AM Hyperlipidemia and Hypertension (Judy Cheng, PharmD, MPH, BCPS, FCCP) – 1.5 credits
11:45 AM – 1:15 PM University Guestings
11:50 AM – 12:50 PM lunch / exhibits
12:50 PM – 2:00 PM Opiates and Benzodiazepines Drug Interaction: Theoretical Risks & Real Outcomes (Michael Angelini, MA, PharmD, BCPP) – 1.0 credit
1:50 PM – 3:50 PM How Did We Get Here? A Review of the Past, Present, and Future of Sterile Compounding (Lawrence Ansel, PharmD, BC-ADM, BCPS, FCCP) – 1.5 credits
3:50 PM – 4:00 PM Post-Activity Assessment & Closing Remarks
4:00 PM – 4:30 PM Online Home Study: Everything But the Kitchen Sink: Hot Topics and Clinical Advances in Pain Management

SPKERS

MICHAEL ANGELINI, MA, PharmD, BCPP
Associate Professor of Pharmacy Practice, MCPHS University
Psychiatric Clinical Pharmacist, St. Luke’s Hospital

JUDY CHENG, PharmD, MPH, BCPS, FCCP
Professor of Pharmacy Practice, MCPHS University
Clinical Pharmacy Specialist, Brigham and Women’s Hospital

JENNIFER GOLDMAN-LEVINE, PharmD, CDE, BC-ADM, FCCP
Professor of Pharmacy Practice, MCPHS University
Clinical Pharmacist, Well Life Medical

ERIC S. KASTANGO, MBA, RHIA, FASHI
Principal, CLINICAL IQ, LLC and CriticalPoint, LLC

Michele L. Matthews, PharmD, MA, PharmD, CPE, BCACP
Principal, CLINICAL IQ, LLC and CriticalPoint, LLC

The Howard L. Reed Annual Conference honors Dr. Reed for a lifetime of dedication and service to the University, and bears his name in recognition of his role in conceiving the program in 1941. It was established as an opportunity for pharmacists to keep abreast of changes in the profession and to familiarize their visit former teachers and new faculty.

GOALS AND OBJECTIVES

AT THE CONCLUSION OF THIS ACTIVITY, PARTICIPANTS SHOULD BE ABLE TO:

CARDIOVASCULAR DISEASE RISK MANAGEMENT.
FOCUS ON NEW RECOMMENDATIONS FOR HYPERLIPIDEMIA AND HYPERTENSION.
UAN #0026-0000-15-002-L01-P | Application-based

- Analyze the clinical evidence supporting the latest recommendations made by the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
- Discuss the controversy surrounding the major changes in the new ACC/AHA Guideline related to LDL-cholesterol targets and statins.
- Analyze the clinical evidence supporting the latest recommendations in hypertension management made by the Eighth Joint National Committee Evidence Based Guideline for the Management of High Blood Pressure in Adults (JNC 8).
- Design the most optimal, patient-specific management plan in developing atherosclerotic cardiovascular disease.

TIPS 2 DIABETES MANAGEMENT:
UPDATE ON NEWER THERAPIES.
UAN #0026-0000-15-006-L01-P | Application-based

- Compare pharmacodynamic interaction with specific types of these drugs.
- Describe the appropriate method for monitoring for drug interactions.
- Develop a rational plan for avoiding this drug interaction by providing safer alternatives.
- Determine the appropriate method for monitoring for the risk of a patient experiencing serious side effects.
- Identify the requirements of a quality system that is consistent with the ACPE Standards regarding commercial support.
- Identify the conditions under which facilities that compound sterile drugs can be exempt from the approval, adequate directions for use, and CGMP requirements under the most optimal, patient-specific therapeutic regimen for patients with type 2 diabetes.
- Determine the most appropriate, patient-specific therapeutic regimen for patients with type 2 diabetes.
- Explain the appropriate method for monitoring for the risk of a patient experiencing serious side effects.
- Identify the requirements of a quality system that is consistent with the ACPE Standards regarding commercial support.
- Identify the conditions under which facilities that compound sterile drugs can be exempt from the approval, adequate directions for use, and CGMP requirements under the most optimal, patient-specific therapeutic regimen for patients with type 2 diabetes.
- Determine the most appropriate, patient-specific therapeutic regimen for patients with type 2 diabetes.

STATIONMENT OF DISCLOSURE:
MCPHS University adheres to the ACPE Standards regarding commercial support of continuing education programs. It is the policy of MCPHS University that the speakers and planning committee disclose real or apparent conflicts of interest relating to the topics of the educational activity, which relevant conflicts of interest are resolved, and also that the speakers and planning committee disclose any proprietary or commercial support of any presentation. Detailed disclosures will be included in the course materials.

MCPHS University reserves the right to cancel this program due to unforeseen circumstances, in which case a full refund will be given to participants. MCPHS University will not be responsible for travel expenses incurred by the participant in the unlikely event that the program is canceled.
AGENDA

7:00 AM – 8:15 AM Registration and Continental Breakfast | Exhibits
8:15 AM – 8:30 AM Welcoming Remarks & Pre-Activity Assessment
8:30 AM – 10:00 AM Cardiovascular Disease Risk Management: Focus on New Recommendations for Hypertension and Hyperlipidemia (Dennis Cheng, PharmD, BCPP, FCPS) – 1.5 credits
10:00 AM – 10:15 AM Break | Exhibits
10:15 AM – 11:45 AM Type 2 Diabetes Management: Update on Newer Therapies (Jennifer Goldman-Levine, PharmD, CDE, BC-ADM, FCCP) – 1.5 credits
11:45 AM – 12:15 PM University Lunch
11:50 AM – 12:50 PM Lunch | Exhibits
12:50 PM – 1:50 PM Opiates and Benzodiazepines Drug Interaction: Theoretical Risks & Real Outcomes (Michael Angelini, MA, PharmD, BCPP) – 1.5 credits
1:50 PM – 3:50 PM How Did We Get Here? A Review of the Past, Present, and Future of Sterile Compounding (Lawrence Goldenstein, PharmD, BC-ADM, FCCP) – 2.0 credits
3:50 PM – 4:00 PM Post-Activity Assessment & Closing Remarks
4:00 PM – 4:15 PM ONLINE HOME STUDY: Everything But the Kitchen Sink: Hot Topics and Clinical Advances in Pain Management (Michael L. Matthew, PharmD, CPE, BCACP) – 2.0 credits

SPKERS

MICHAEL ANGELINI, MA, PharmD, BCPP
Associate Professor of Pharmacy Practice, MCPHS University
Psychiatric Clinical Pharmacist, St. Luke’s Hospital

JUDY CHENG, PharmD, MPH, BCPS, FCOP
Professor of Pharmacy Practice, MCPHS University
Clinical Pharmacy Specialist, Brigham and Women’s Hospital

JENNIFER GOULDMAN-LEVINE, PharmD, CDE, BC-ADM, FCPP
Professor of Pharmacy Practice, MCPHS University
Clinical Pharmacist, Well Life Medical

ERIC S. NASTASIO, MBA, RHIA, FASHIS
Principal, CLINICAL AL, LLC and CriticalPoint

ONLINE HOME STUDY:

MICHLE L. MATTHEWS, PharmD, CPE, BCACP
Associate Professor of Pharmacy Practice, MCPHS University
Principal, CLINICAL IQ, LLC and CriticalPoint

ONLINE HOME STUDY: EVERYTHING BUT THE KITCHEN SINK: HOT TOPICS AND CLINICAL ADVANCES IN PAIN MANAGEMENT

GOALS AND OBJECTIVES

AT THE CONCLUSION OF THIS ACTIVITY, PARTICIPANTS SHOULD BE ABLE TO:

CARDIOVASCULAR DISEASE RISK MANAGEMENT: FOCUS ON NEW RECOMMENDATIONS FOR HYPERTENPNIOS AND HYPERLIPIDEMIA

UAN #0025-0000-15-032-LEP-1 / Application-based

• Describe the evidence supporting the latest recommendations made by the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
• Discuss the controversy surrounding the major changes in the new ACC/AHA Guideline related to LDL-cholesterol targets and statins.
• Analyze the clinical evidence supporting the latest recommendations in hypertension management made by the Eighth Joint National Committee Evidence Based Guideline for the Management of High Blood Pressure in Adults (JNC 8).
• Design the most optimal, patient-specific management plan in reducing patient’s risk in developing atherosclerotic cardiovascular disease.

DIABETES MANAGEMENT: UPDATE ON NEWER THERAPIES

UAN #0025-0000-15-033-LEP-1 / Application-based

• Discuss glycolytic goals and targets as identified by ADA & AACE guidelines based on patient’s individual characteristics and needs.
• Compare and contrast the ADA and AACE recommendations for newer drug therapies.
• Identify the mechanisms of action, side effects, efficacy, safety, and tolerability for newer agents, such as DPP-4 inhibitors, GLP-1 RAs and SGLT2 inhibitors, as well as the treatment of type 2 Diabetes.
• Design the most appropriate, patient-specific therapeutic regimen for patients with type 2 Diabetes.

STERILE COMPOUNDING SMOKES INTERATION: THEORETICAL RISKS & REAL OUTCOMES

UAN #0025-0000-15-034-LEP-1 / Knowledge-based

• Describe the pharmacodynamics interaction with amines and benzonemides and the pharmacokinetic interaction between specific types of these drugs.
• Develop a rational plan for avoiding this drug interaction by providing safer alternatives.
• Determine the appropriate method for monitoring for amines when a patient requires concurrent therapy of an opiate and benzodiazepine.

HOW DID WE GET HERE? A REVIEW OF THE PAST, PRESENT, AND FUTURE OF STERILE COMPOUNDING

UAN #0025-0000-15-023-LEO-1 / Knowledge-based

• Explain the history of sterile compounding legislation.
• Describe the current regulatory environment for pharmacies that compound sterile preparations.
• Determine the requirements of a quality system that ensures a consistent aseptic compounding state of control.
• Identify the conditions under which facilities that compound sterile drugs may be allowed the approval, appropriate directions for use, and COMPS requirements under sections 503A of the Federal Food, Drug, and Cosmetic Act (FFDCA) and the approval and adequate directions for use provisons under section 503B of the FFDCA.

STATEMENT OF DISCLOSURE: MCPHS University adheres to the ACCME Standards regarding commercial support of continuing education. It is the policy of MCPHS University that the speakers and planning committee disclose real or apparent conflicts of interest relating to the topics of the educational activity, that relevant conflicts of interest are resolved, and also that a speaker who has an actual or potential conflict of interest will be given to participants. MCPHS University will not be responsible for travel expenses incurred by the participant in the unlikely event that the program is canceled.

Questions? Contact MCPHS CE at continuing.education@mcphs.edu or 617.732.2220.
LOCATION AND LODGING

LOCATION: GILLETTE STADIUM
One Patriot Place | Foxborough, MA 02035
Conference entrance:
West Club (W1 Putnam Club)
Visit alumni.mcphs.edu/reed2015 for driving directions and a detailed map of the appropriate stadium entrance.

LODGING:
RENAISSANCE HOTEL & SPA AT PATRIOT PLACE
(Adjacent to Gillette Stadium)
28 Patriot Place, Foxborough, MA 02035
508.543.3500 / 866.580.6396
www.renaissancepatriotplace.com
Special Room Rate: $179 single/double plus applicable tax
Booking Deadline: February 11, 2015
Booking Method: Visit alumni.mcphs.edu/reed2015 for a special booking link or call the phone number above and mention the MCPHS Reed Conference.
Other lodging options are listed at alumni.mcphs.edu/reed2015.

ACCREDITATION
MCPHS University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants will receive 6.0 contact hours (0.6 CEUs), including two hours of pharmacy law, for the live activity and are eligible to complete a complimentary 2.0 hour home study (0.2 CEUs), for a total of 8.0 contact hours (0.8 CEUs).

REQUIREMENTS FOR CREDIT:
Partial credit will not be awarded. All participants must return a signature sheet at the conclusion of the activity to claim credit, as well as log into the MCPHS website, insert the specific activity code for each session, and complete the evaluation. CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours.
Attendance will be verified. Credit will not be issued to participants who arrive more than 15 minutes after the start of that particular session or to those who depart early. Credit cannot be awarded to individuals who complete the activity evaluation(s) more than 60 days post activity.

EVALUATION:
All participants will have the opportunity to review the educational sessions and speakers and to identify future educational needs.

SUPPORT:
A complete list of grant support will be available on the day of the activity.